

PRIOR AUTHORIZATION REQUEST FORM

Antiemetics for Chemotherapy Induced Nausea and Vomiting

Akynzeo (netupitant and palonosetron) Capsules, Anzemet® (dolasetron) tablets, aprepitant capsules, Sancuso® (granisetron) patch, Sustol® (granisetron) subcutaneous injection, Varubi® (rolapitant) tablets, Zuplenz® (ondansetron) film

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred:

NK1 antagonist: Cinvanti® IV (aprepitant), Emend® IV (aprepitant), Emend IV® (fosaprepitant)
 5-HT3 antagonist: granisetron, ondansetron, palonosetron

Non-preferred:

NK1 antagonist: aprepitant oral capsules, Varubi® (rolapitant) tablets
 5-HT3 antagonists: Sancuso® (granisetron) patch, Sustol® (granisetron) SQ injection, Zuplenz® (ondansetron) film
 5-HT3/NK1 combination: Akynzeo® (netupitant/palonsetron) capsules

Dosing/Frequency: _____

Questions	Yes	No	Comments/Notes
AKYNZEO®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Has the member tried and failed aprepitant and fosaprepitant in combination with palonosetron?			
ANZEMET®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • ondansetron • granisetron • palonosetron injection 			

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

APREPITANT ORAL CAPSULES			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Has the member tried and failed IV aprepitant and IV fosaprepitant in combination with palonosetron?			
SANCUSO®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • ondansetron • granisetron • Anzemet® tablets • palonosetron injection 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
SUSTOL®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • Ondansetron • Granisetron • Anzemet® tablets • Palonosetron injection • Sancuso patch 			
VARUBI®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Has the member tried and failed aprepitant and fosaprepitant?			
ZUPLENZ®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. If yes to question 1, has the member tried and failed all of the following: <ul style="list-style-type: none"> • Ondansetron • Granisetron • Palonosetron injection • Anzemet® 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

Additional information:

Physician Signature:

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 006
Origination Date: 06/22/2018
Reviewed/Revised Date: 08/19/2020
Next Review Date: 08/19/2021
Current Effective Date: 09/01/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.